Detection of NRG1 Gene Fusions in Solid Tumors

Sushma Jonna1, Rebecca A. Feldman2, Jeffrey Swensen2, Zoran Gatalica2, Wolfgang M. Korn2, Hossein Borghaei3, Patrick C. Ma4, Jorge J. Nieva5, Alexander I. Spira6, Ari M. Vanderwalde7, Antoinette J. Wozniak8, Edward S. Kim9, and Stephen V. Liu1

Abstract

Purpose: NRG1 gene fusions are rare but potentially actionable oncogenic drivers that are present in some solid tumors. Details regarding the incidence of these gene rearrangements are lacking. Here, we assessed the incidence of NRG1 fusions across multiple tumor types and described fusion partners.

Experimental Design: Tumor specimens submitted for molecular profiling at a Clinical Laboratory Improvement Amendments (CLIA)–certified genomics laboratory and that underwent fusion testing by anchored multiplex PCR for targeted RNA sequencing were retrospectively identified. The overall and tumor-specific incidence was noted, as was the specific fusion partner.

Results: Out of 21,858 tumor specimens profiled from September 2015 to December 2018, 41 cases (0.2%) harbored an NRG1 fusion. Multiple fusion partners were identified. Fusion events were seen across tumor types. The greatest incidence was in nonsmall cell lung cancer (NSCLC, 25%), though this represented only 0.3% of NSCLC cases tested. Other tumor types harboring an NRG1 fusion included gallbladder cancer, renal cell carcinoma, bladder cancer, ovarian cancer, pancreatic cancer, breast cancer, neuroendocrine tumor, sarcoma, and colorectal cancer.

Conclusions: NRG1 fusions can be detected at a low incidence across multiple tumor types with significant heterogeneity in fusion partner.

See related commentary by Dimou and Camidge, p. 4865

Introduction

Appropriate management of advanced non–small cell lung cancer (NSCLC) is guided by the presence or absence of specific molecular drivers. The identification of activating genomic alterations in EGFR, ALK, ROS1, or BRAF not only provides insight into the underlying biology but also directs initial and subsequent therapeutic decisions (1–5). It is now standard-of-care to search for these mutations and fusions in all patients with nonsquamous NSCLC (6). It has also become clear that some molecular drivers will serve as therapeutic targets across multiple tumor types (7). including the tumor agnostic approval of larotrectinib for tumors with a gene fusion in NTRK1, NTRK2, or NTRK3 (8). As our understanding of cancer grows increasingly sophisticated, additional drivers have surfaced that may have a similar impact on evolving treatment paradigms.

Neuregulin-1 (NRG1) gene fusions are an emerging, potentially actionable oncogenic driver (9). NRG1 fusions can promote pathologic signaling via MAPK and other canonical pathways (10). When NRG1 fusions are present, targeting ERBB2 and ERBB3 has been an effective treatment strategy in vitro. Recently, clinical responses to tyrosine kinase inhibitors and mAbs have also been reported (9, 11–13).

The interest in evaluating the prevalence of NRG1 fusions has increased given the potential therapeutic implications of this genetic alteration. Because the original description of the CD74–NRG1 gene fusion in invasive mucinous lung adenocarcinoma, detection has been noted in other tumor types, both de novo and as a resistance mechanism in ALK-rearranged NSCLC (9, 14–16). Here, we report the incidence and characteristics of NRG1 fusions across a variety of tumor types based on a large molecular profiling experience.

Materials and Methods

Patient cohort

An institutional review board (IRB)–approved, retrospective assessment of a deidentified molecular profiling database was surveyed for solid tumors that underwent fusion testing. From a cohort including all cases submitted to a Clinical Laboratory Improvement Amendments (CLIA)–certified laboratory (Caris Life Sciences) for comprehensive genomic profiling from September 2015 to December 2018, all unique cases that underwent successful fusion testing for targeted RNA sequencing were identified. In addition, all histologic characteristics were reviewed by a board-certified pathologist (Z. Gatalica).

Gene fusion detection

Prior to any molecular analysis, H&E-stained sections of formalin-fixed paraffin-embedded (FFPE) tumor tissue were manually assessed by board-certified pathologists for tumor
NRG1 Fusions in Solid Tumors

**Translational Relevance**

NRG1 fusions are potentially actionable genomic events seen in various tumor types. While there are reports of therapeutic efficacy with agents that target Erb-B2/Erb-B3, little is known about the characteristics of these fusions. Here, we report the incidence of NRG1 fusions in a large cohort of solid tumors that underwent RNA sequencing. NRG1 fusions were detected at a low incidence across many solid tumor types. Multiple fusion partners were identified, which will influence the development of strategies to detect these events on a large scale.

Results

**Sample population**

From September 2015 to December 2018, a total of 21,858 tumor specimens from unique patients were successfully evaluated. The tumor types included NSCLC (n = 9,592), glioma (n = 1,997), colorectal cancer (n = 1,690), breast cancer (n = 1,106), bladder cancer (n = 945), ovarian cancer (n = 686), sarcoma (n = 627), pancreatic adenocarcinoma (n = 623), gallbladder cancer (n = 580), other gynecologic malignancies (e.g., uterine, cervical, vulvar; n = 524), melanoma (n = 360), prostate cancer (n = 261), gastric adenocarcinoma (n = 239), head and neck squamous cell carcinoma (n = 236), thyroid cancer (n = 219), renal cell carcinoma (n = 211), neuroendocrine tumors (n = 203), esophageal cancer (n = 202), small-cell lung cancer (n = 107), extralepatic bile duct cancer (n = 98), small bowel cancer (n = 98), gastrointestinal stromal tumor (n = 83), hepatocellular carcinoma (n = 83), thymic cancer (n = 31), testicular cancer (n = 25), and other malignancies (n = 1,032).

**Incidence**

The incidence of NRG1 fusions in the entire tested population was 0.2% (41/21,858). Incidence varied by tumor type (Fig. 1): 0.5% gallbladder cancer (3/580), 0.5% pancreatic cancer (3/623), 0.5% renal cell carcinoma (1/211), 0.4% ovarian cancer (3/686), 0.3% NSCLC (25/9,592), 0.2% breast cancer (21/1,106), 0.2% sarcoma (1/627), 0.1% bladder cancer (1/945), and 0.1% colorectal cancer (1/690). The remaining identified NRG1 fusion was in a patient with a neuroendocrine tumor of the nasopharynx. Table 1 describes the characteristics of the 41 patients found to have an NRG1 fusion. The most common histologic subtype was adenocarcinoma (70%), of which 24% were classified as mucinous adenocarcinoma and another 8% had a mixed histology with a mucinous component (Supplementary Fig. S1). The majority of cases were stage IV at the time of fusion detection. NRG1 fusion events were more frequently identified in females (66%) versus males, and most specimens were procured from the primary site (68%) compared with a distant metastasis (32%). In the total cohort, 51% (11,228/21,858) of patients were females and 59% (10,629/21,858) of specimens profiled were from primary sites.

**Fusion partners**

The specific fusion partners were also diverse within and across malignancies (Supplementary Table S1; Figs. 2–5; Supplementary Fig. S2). In NSCLC, CD74 was the most common fusion partner (n = 12), but other detected partners in NSCLC cases included SDC4 (n = 3), SLC3A2 (n = 1), TNC (n = 1), MDK (n = 1), ATP1B1 standards. Only pathogenic or presumed pathogenic mutations were considered deleterious and included for assessment of comutation patterns with NRG1 fusion–positive cases.

IHC

IHC was performed using commercially available detection kits and automated staining techniques (Benchmark XT, Ventana; and Autostainer Link 48, Dako). Primary antibodies tested were as follows: Her2/neu (485, Ventana), pan-TRK (C17F1, Cell Signaling Technology), and ALK (DSF3, Ventana). Cutoffs for positive staining: (1) pan-TRK, ≥1% of cells, (2) Her2, ≥3+ and ≥10%, and (3) ALK, ≥3+ and ≥10%.

NGS

NGS was performed on isolated genomic DNA using the Illumina NextSeq platform. A custom-designed SureSelect XT assay was used to enrich 592 whole-gene targets (Agilent Technologies). All variants were detected with >99% confidence based on allele frequency and amplicon coverage, with an average sequencing depth of coverage of >500 and an analytic sensitivity of 5%. For variant classification, variants of genes that were predetermined for their cancer-related and clinical significance were interpreted by board-certified molecular geneticists and categorized as pathogenic, presumed pathogenic, variant of unknown significance, presumed benign, or benign according to American College of Medical Genetics and Genomics (ACMG)
In the other malignancies, the identified fusion partners were as follows: SETD4, TSHZ2, and ZMYM2 in ovarian cancer; ADAM9 and COX10-AS1 in breast cancer; ATP1B1, CDH1, and VTCN1 in pancreatic cancer; NOTCH2 and ATP1B1 (n = 2) in gall bladder cancer; POMK in colorectal cancer; RBPMS in renal cell carcinoma; GDF15 in urothelial bladder cancer; WHSC1L1 in sarcoma; and HMBOX1 in neuroendocrine tumor of the nasopharynx. Of the 41 NRG1 fusions identified, 34 were in-frame, three were out-of-frame variants of unknown significance, and four were translated variants.

Co-occurrence with other genetic aberrations

NRG1 fusions were mutually exclusive with oncogenic alterations in EGFR, KRAS, ALK, ROS1, and RET (Fig. 2). One case co-occurred with a BRAF G466A mutation, one with a KRAS G12D mutation, and three with NF1 or NF2 mutations (NF1, Q616fs, NSCLC and c.204+1G>T, ovarian; NF2, H242fs, NSCLC). Most cases (n = 30) also demonstrated concurrent mutations in tumor suppressor genes, including TP53.

Survival

Limited survival analysis is shown in Supplementary Fig. S3 for patients with full annotation (n = 7). Median survival for

---

Table 1. Patient and tumor characteristics for NRG1 fusion-positive cases

<table>
<thead>
<tr>
<th>Total, n</th>
<th>NSCLC</th>
<th>Ovarian cancer</th>
<th>Breast cancer</th>
<th>GI cancers</th>
<th>GU cancers</th>
<th>Other</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total, n</td>
<td>25</td>
<td>3</td>
<td>2</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>41</td>
</tr>
<tr>
<td>Median age, range</td>
<td>71 (52-90)</td>
<td>53 (47-69)</td>
<td>44 (38-49)</td>
<td>46 (37-68)</td>
<td>61 (58-63)</td>
<td>59 (36-81)</td>
<td>68 (36-90)</td>
</tr>
<tr>
<td>Sex, n, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>8 (32%)</td>
<td>3 (43%)</td>
<td>2 (100%)</td>
<td>4 (57%)</td>
<td>1 (50%)</td>
<td>2 (100%)</td>
<td>14 (34%)</td>
</tr>
<tr>
<td>Female</td>
<td>17 (68%)</td>
<td>2 (100%)</td>
<td>7 (100%)</td>
<td>2 (50%)</td>
<td>1 (50%)</td>
<td>27 (66%)</td>
<td></td>
</tr>
<tr>
<td>Group stage, time of biopsy, n, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>1 (5%)</td>
<td>2 (100%)</td>
<td>7 (100%)</td>
<td>2 (50%)</td>
<td>1 (50%)</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>3 (14%)</td>
<td>3 (100%)</td>
<td>2 (100%)</td>
<td>4 (57%)</td>
<td>1 (50%)</td>
<td>27 (66%)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>6 (27%)</td>
<td>1 (33%)</td>
<td>7 (100%)</td>
<td>2 (100%)</td>
<td>6 (17%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>12 (54%)</td>
<td>3 (100%)</td>
<td>2 (100%)</td>
<td>7 (100%)</td>
<td>2 (100%)</td>
<td>26 (72%)</td>
<td></td>
</tr>
<tr>
<td>Histology, n, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>29 (70%)</td>
<td>3 (100%)</td>
<td>3 (100%)</td>
<td>3 (100%)</td>
<td>3 (100%)</td>
<td>29 (70%)</td>
<td></td>
</tr>
<tr>
<td>Papillary</td>
<td>1 (4%)</td>
<td>3 (100%)</td>
<td>2 (100%)</td>
<td>7 (100%)</td>
<td>2 (50%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucinous</td>
<td>6 (24%)</td>
<td>1 (33%)</td>
<td>2 (67%)</td>
<td>1 (33%)</td>
<td>2 (50%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acinar</td>
<td>2 (8%)</td>
<td>2 (100%)</td>
<td>1 (50%)</td>
<td>2 (50%)</td>
<td>2 (50%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixed</td>
<td>3 (12%)</td>
<td>1 (100%)</td>
<td>6 (100%)</td>
<td>1 (33%)</td>
<td>2 (50%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>2 (8%)</td>
<td>1 (50%)</td>
<td>1 (50%)</td>
<td>1 (33%)</td>
<td>2 (50%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NO'S</td>
<td>8 (32%)</td>
<td>2 (100%)</td>
<td>2 (100%)</td>
<td>2 (100%)</td>
<td>2 (50%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>2 (8%)</td>
<td>1 (50%)</td>
<td>1 (50%)</td>
<td>1 (33%)</td>
<td>2 (50%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serous carcinoma</td>
<td>2 (67%)</td>
<td>1 (50%)</td>
<td>1 (50%)</td>
<td>1 (33%)</td>
<td>2 (50%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1 (4%)</td>
<td>1 (33%)</td>
<td>1 (33%)</td>
<td>1 (33%)</td>
<td>1 (33%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specimen site, n, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>20 (80%)</td>
<td>5 (20%)</td>
<td>2 (100%)</td>
<td>4 (57%)</td>
<td>1 (50%)</td>
<td>28 (68%)</td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td>3 (100%)</td>
<td>3 (43%)</td>
<td>1 (50%)</td>
<td>1 (50%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: GI, gastrointestinal; GU, genitourinary; NOS, not otherwise specified.

*Pancreatic ductal adenocarcinoma, gallbladder cancer (cholangiocarcinoma), and colorectal cancer.
*Renal cell carcinoma and urethelial bladder cancer.
*Soft tissue sarcoma of the extremity/trunk and neuroendocrine tumor of the nasopharynx.
*Mixed histology (2 patients with acinar, clear cell, and mucinous components and 1 patient with adenosquamous features).
*Other, pleomorphic carcinoma or sarcoma, carcinosarcoma, clear cell carcinoma, or neuroendocrine tumor.
the entire cohort was 638 days and varied by tumor type, although analysis is limited by the small sample size.

**Discussion**

NRG1 gene fusions represent a novel oncogenic driver across cancer types. These rare genomic events can generate proteins that retain the extracellular EGF-like domain of NRG1 and the transmembrane domain of the specific fusion partner. These proteins then serve as ligands for ERBB3 (HER3) and ERBB4 (HER4) receptors (10). ERBB3 can then be activated through juxtacrine signaling from the EGF-like domain and autocrine signaling of secreted NRG1 (19). Subsequent heterodimerization of ERBB3 with ERBB2 activates downstream signaling important in tumor genesis mediated by pathways including ERK, PI3K, AKT, and NFκB, described in cell models (9, 19).

In this report, we retrospectively analyzed over 21,000 specimens after RNA sequencing using the ArcherDx platform to detect NRG1 fusions. As previously reported, our study confirmed the occurrence of NRG1 fusions in NSCLC, breast cancer, cholangiocarcinoma, ovarian cancer, and pancreatic cancer with a low overall incidence. Here, we also detected NRG1 fusions in colorectal cancer, sarcoma, and a neuroendocrine tumor of the nasopharynx, which had not been previously reported. In this report, the majority of these tumors (70%) were adenocarcina

![Figure 2. Genomic features observed in NRG1-fusion-positive solid tumors. Oncoprint plot illustrating co-occurrence of driver events, genes with any pathogenic variant detected in the cohort, and other clinically relevant protein markers. Each NRG1-fusion-positive sample corresponds to one row in the table; frame prediction of the fusion, cancer type, and fusion partner is provided. Fill of boxes correlates with gene/protein status: (i) red, pathogenic variant detected or positive expression, (ii) gray, wild-type or low/negative expression, and (iii) white, test was not performed or indeterminate. Pathogenic variants in oncogenes were rare, but at least one mutation in tumor suppressor genes, including TP53, occurred in all but nine samples. CDS, coding sequence; CRC, colorectal cancer; DNA-seq, DNA sequencing; GBC, gallbladder cancer (cholangiocarcinoma); HR+ breast, hormone receptor-positive breast; NET, neuroendocrine tumor of the nasopharynx; PDAC, pancreatic ductal adenocarcinoma; RCC, renal cell carcinoma; RNA-seq, RNA sequencing; TN breast, triple-negative breast; UC, urothelial bladder cancer; VUS, fusion variant of unknown significance.](https://www.aacrjournals.org/doi/figure/10.1158/1078-0432.CCR-19-0160)
noncoding exons of fusion partner genes. In each of these cases \(n = 4\); Supplementary Table S1), a codon encoding for methionine is present a short distance into exon 2 of NRG1 that could potentially act as a translation initiation codon; if functional, the fusion partner could be providing the promoter for a likely N-terminal truncated version of NRG1. These observations are consistent with similar studies where NRG1 fusion variants included chimeric proteins and cases where expression of NRG1 is controlled by the promoter of the 5' partner (21). Alternative methodologies are needed to confirm expression of the transcripts identified in this study to determine their significance.

Additional studies describing NRG1 fusions suggest these events are mutually exclusive with other known molecular drivers (14). This was consistent with the findings in this report. Specifically, all NSCLC cases were ALK, ROS, RET fusion–negative, and KRAS wild-type, and all pancreatic adenocarcinomas were KRAS wild-type. The exception was one colorectal cancer case that also harbored a KRAS G12D mutation. The remainder of the cases studied harbored several pathogenic variants in tumor suppressor genes including TP53 and DNA damage and response genes (CHEK2, BRCA2, WRN).

NRG1 fusions are detected in a variety of tumor types. In 2014, Fernandez-Cuesta and colleagues first described the CD74–NRG1

Figure 3.
NRG1 fusion partners. Pie chart showing the proportion and variety of fusion partners for NRG1.

Figure 4.
Circos plot depicting NRG1 fusion genes and partners from Supplementary Table S1. NRG1 and partners in NSCLC (A) and all other tumors (B). chr, chromosome.
Gene fusion in five female never-smokers whose tumors lacked known activating mutations (10). As comprehensive molecular profiling and RNA sequencing has become more prevalent, NRG1 fusions have been detected in a variety of other tumor types, including breast, ovarian, and pancreatic cancer (14, 15). Analysis of MSK-IMPACT dataset including NGS and the MSK solid fusion assay identified 10 patients with NRG1 fusions (out of 17,485 tested): seven in lung adenocarcinoma, two in pancreatic cancer, and one in breast cancer. Further analysis with RNA sequencing revealed additional fusions in other tumor types including ovarian cancer, uterine carcinosarcoma, renal clear cell carcinoma, prostate cancer, and head and neck cancer (9).

As NRG1 alterations activate the ERBB2/ERBB3 signaling pathway, targeted treatment with inhibitors of this pathway is an appealing therapeutic strategy. Dual targeting of ERBB2 and ERBB3 has also been evaluated in preclinical models (22, 23). Afatinib, a pan-ERBB inhibitor, was successfully utilized in this manner, and several patients with tumor harboring an NRG1 fusion achieved durable benefit with afatinib (11–13). Response to an ERBB3 mAb, GSK2849330, has also been reported (9). Combining an ERBB3 mAb and an EGFR tyrosine kinase inhibitor was also effective in a small case series (24). Prospective studies are needed to define the role of targeted therapy for patients with tumors harboring NRG1 fusions, but these data suggest that NRG1 fusions represent a novel potential target across many tumor types that warrant further study.

Disclosure of Potential Conflicts of Interest

W.M. Korn is a consultant/advisory board member for Merck Sharp & Dohme. H. Bonghari reports receiving commercial research grants from Bristol-Myers Squibb and Lilly, and is a consultant/advisory board member for Bristol-Myers Squibb, Lilly, AstraZeneca, Merck, Genentech, Regeneron, Celgene, Genmab, Amgen, EMD Serono, Boehringer Ingelheim, and Takeda.

P.C. Ma reports receiving speakers bureau honoraria from AstraZeneca,
Jonna et al.

Merck, Bristol-Myers Squibb, Bayer, and Takeda, and is a consultant/advisory board member for AstraZeneca, Apollonics, and Caris Life Sciences. A.J. Spira is a consultant/advisory board member for Foundation Medicine. A.M. Vanderwalde reports receiving commercial research grants from Amgen and Caris Life Sciences, and is a consultant/advisory board member for AstraZeneca, Bristol-Myers Squibb, Genentech, Compugen, and Immunocore. A.J. Wozniak reports receiving commercial research grants from Boehringer Ingelheim and Genentech, and is a consultant/advisory board member for AstraZeneca, Boehringer Ingelheim, Takeda, Coherus, Karyopharm, Premier, H.I.Y.A. Bioscience, and BeyondSpring. S.V. Liu reports receiving commercial research grants from AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Clovis, ExaneX, Genentech/Roche, Ignyta, Lilly, Lyceum, Merck, Molecular Partners, OncoMed, P.C. Ma, J.J. Nieva, A.M. Vanderwalde, A.J. Wozniak, and S.V. Liu. A.J. Wozniak reports receiving commercial research grants from AstraZeneca, Roche, Ignyta, Janssen, Lilly, Merck, Pfizer, Regeneron, Taiho, Takeda, and G1 Therapeutics. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: S. Jonna, R.A. Feldman, Z. Gatalica, A.M. Vanderwalde, S.V. Liu
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Jonna, R.A. Feldman, Z. Gatalica, H. Borchai, P.C. Ma, J.J. Nieva, A.M. Vanderwalde, A.J. Wozniak, S.V. Liu

Writing, review, and/or revision of the manuscript: S. Jonna, R.A. Feldman, Z. Gatalica, W.M. Korn, H. Borchai, P.C. Ma, J.J. Nieva, A.I. Spira, A.M. Vanderwalde, A.J. Wozniak, E.S. Kim, S.V. Liu

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Jonna, R.A. Feldman, J. Swensen, S.V. Liu

Study supervision: A.M. Vanderwalde, S.V. Liu

Acknowledgments

The authors thank Alfredo Moreno for support designing the figures and Michele Saul for the analysis of survival data. The authors received no specific funding for this work.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 15, 2019; revised March 4, 2019; accepted April 8, 2019; published first April 15, 2019.

References

Detection of NRG1 Gene Fusions in Solid Tumors

Sushma Jonna, Rebecca A. Feldman, Jeffrey Swensen, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-19-0160

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2019/04/13/1078-0432.CCR-19-0160.DC1

Cited articles
This article cites 24 articles, 9 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/25/16/4966.full#ref-list-1

Citing articles
This article has been cited by 8 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/25/16/4966.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/25/16/4966.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.